MindMed to Participate at the LifeSci Partners 11th Annual Corporate Access Event

Rhea-AI Summary

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) will participate in the LifeSci Partners 11th Annual Corporate Access Event from January 5-7, 2022. CEO Robert Barrow is scheduled to take part in a panel titled "Psychedelics: More Than Just a Trip" on January 5 at 10:00 AM ET. The event will be held virtually, with a webcast available here. MindMed is pioneering psychedelic-inspired therapies aimed at addressing mental health issues and addiction, with a promising pipeline of treatments.

NEW YORK, Dec. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer and Director, Robert Barrow, will be participating in a panel and in one-on-one investor meetings at the LifeSci Partners 11^th Annual Corporate Access Event, to be held virtually January 5-7, 2022.

Details on the panel discussion can be found below.

     Topic: "Psychedelics: More Than Just a Trip"             

     Date: Wednesday, January 5, 2022

     Time: 10:00 AM ET

     Webcast link: Click Here 

A replay link of the panel discussion will also be available on MindMed's website.

About MindMed

MindMed is a clinical-stage biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address mental health and addiction. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

For Media: media@mindmed.co

For Investors: ir@mindmed.co

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-at-the-lifesci-partners-11th-annual-corporate-access-event-301451687.html

SOURCE Mind Medicine (MindMed) Inc.

FAQ

What is MindMed's participation in the LifeSci Partners 11th Annual Corporate Access Event?

MindMed will participate in the event from January 5-7, 2022, with CEO Robert Barrow presenting.

When is MindMed's panel discussion scheduled at the event?

The panel discussion is on January 5, 2022, at 10:00 AM ET.

What is the topic of MindMed's panel discussion at the event?

The topic is "Psychedelics: More Than Just a Trip."

Where can I watch the MindMed panel discussion?

The panel can be viewed via a webcast link, available on the LifeSci Partners website.

What are MindMed's primary focuses in drug development?

MindMed focuses on developing psychedelic-inspired therapies for mental health and addiction.

What is MindMed's stock symbol?

MindMed trades under the symbol MNMD on the NASDAQ.